← Leaderboards
Brion S Maher
Virginia Commonwealth University
$13,542,962
Attributed
$23,122,653
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,122,653 · 8
By mechanism
R01$16,241,216 · 5
T32$6,261,076 · 1
R03$620,361 · 2
Top collaborators
- Renee M. Johnson9 shared
- Adam Peter Spira7 shared
- Julia W Felton5 shared
- Gregory D Kirk5 shared
- Jill Alexandra Rabinowitz5 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Seth Michael Dever$69,611
- Sara Nass$514,598
- Raymond J Colello$2,217,419
- Ying Anna Pun$11,368
- Dewey Taylor$1,351,044
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposSamplingGeneticPathway InteractionsNational Institute Of Drug AbuseGenotypeLinkCohortInvestigationGenome Wide Association StudyPhenotypePublic HealthGenome-WideCommunitiesBaltimoreTraitPreventionBiologicalEpidemiologyEpigenetic ProcessEtiologyBaseGenetic RiskInnovation
Grant awards (38)
Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD$866,527
R01 · FY2025 · AG
NIDA Epidemiology Training Program$860,329
T32 · FY2025 · DA · contact PI
An Examination of the Joint Contributions of Socioeconomic Disadvantage, Genetics, and COVID-19 on the Development of Delay Discounting and Substance Use Across Adolescence$339,238
R01 · FY2025 · DA
Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD$928,646
R01 · FY2024 · AG
NIDA Epidemiology Training Program$351,695
T32 · FY2024 · DA · contact PI
An Examination of the Joint Contributions of Socioeconomic Disadvantage, Genetics, and COVID-19 on the Development of Delay Discounting and Substance Use Across Adolescence$346,893
R01 · FY2024 · DA
NIDA Epidemiology Training Program$139,999
T32 · FY2024 · DA · contact PI
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$1,102,432
R01 · FY2023 · DA · contact PI
Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD$913,303
R01 · FY2023 · AG
NIDA Epidemiology Training Program$803,354
T32 · FY2023 · DA · contact PI
Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD - Microbiome Admin Suppl$404,554
R01 · FY2023 · AG
An Examination of the Joint Contributions of Socioeconomic Disadvantage, Genetics, and COVID-19 on the Development of Delay Discounting and Substance Use Across Adolescence$382,966
R01 · FY2023 · DA
Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD - INCLUDE Admin Suppl$373,336
R01 · FY2023 · AG
An Examination of the Joint Contributions of Socioeconomic Disadvantage, Genetics, and COVID-19 on the Development of Delay Discounting and Substance Use Across Adolescence$1
R01 · FY2023 · DA
NIDA Epidemiology Training Program$931,876
T32 · FY2022 · DA · contact PI
Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD$871,255
R01 · FY2022 · AG
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$850,704
R01 · FY2022 · DA · contact PI
An Examination of the Joint Contributions of Socioeconomic Disadvantage, Genetics, and COVID-19 on the Development of Delay Discounting and Substance Use Across Adolescence$434,628
R01 · FY2022 · DA
NIDA Epidemiology Training Program$888,297
T32 · FY2021 · DA · contact PI
Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD$763,872
R01 · FY2021 · AG
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$960,711
R01 · FY2020 · DA · contact PI
NIDA Epidemiology Training Program$626,363
T32 · FY2020 · DA · contact PI
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$1,468,790
R01 · FY2019 · DA · contact PI
NIDA Epidemiology Training Program$844,138
T32 · FY2019 · DA · contact PI
Functional Genomics and Epigenomics in HIV of Longitudinal Injection Drug Use Trajectory$519,275
R01 · FY2019 · DA · contact PI
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$1,389,208
R01 · FY2018 · DA · contact PI
NIDA Epidemiology Training Program$815,025
T32 · FY2018 · DA · contact PI
Functional Genomics and Epigenomics in HIV of Longitudinal Injection Drug Use Trajectory$599,956
R01 · FY2018 · DA · contact PI
Functional Genomics and Epigenomics in HIV of Longitudinal Injection Drug Use Trajectory$694,661
R01 · FY2017 · DA · contact PI
Genes, Environment and Drug Use in Three Baltimore Cohorts$243,000
R01 · FY2017 · DA · contact PI
Functional Genomics and Epigenomics in HIV of Longitudinal Injection Drug Use Trajectory$643,821
R01 · FY2016 · DA · contact PI
Genes, Environment and Drug Use in Three Baltimore Cohorts$240,570
R01 · FY2016 · DA · contact PI
Functional Genomics and Epigenomics in HIV of Longitudinal Injection Drug Use Trajectory$659,869
R01 · FY2015 · DA · contact PI
Genes, Environment and Drug Use in Three Baltimore Cohorts$243,000
R01 · FY2015 · DA · contact PI
Genetic Epidemiology of HIV Risk Behavior Trajectory in the ALIVE Cohort$162,000
R03 · FY2014 · DA · contact PI
Genetic Epidemiology of HIV Risk Behavior Trajectory in the ALIVE Cohort$162,000
R03 · FY2013 · DA · contact PI
Statistical Genetic Analysis of Orofacial Cleft Families$147,361
R03 · FY2008 · DE · contact PI
Statistical Genetic Analysis of Orofacial Cleft Families$149,000
R03 · FY2007 · DE · contact PI